Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment—A nationwide register‐based study
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
AbstractBackgroundSafety data for different anticoagulant medications in venous thromboembolism (VTE) are scarce, in particular for extended treatment.ObjectivesTo compare major bleeding rates depending on the choice of anticoagulation during initial (first 6 months) and extended treatment (6 months up to 5 years).MethodsA nationwide register‐based study including cancer‐free patients with a first‐time VTE between 2014 and 2020. Cox proportional hazards models were used to compare bleeding rates.ResultsWe included 6558 patients on warfarin, 18,196 on rivaroxaban, and 19,498 on apixaban. At 6 months, 4750 (72.4%) remained on warfarin, 11,366 (62.5%) on rivaroxaban, and 11,940 (61.2%) on apixaban. During initial treatment, major bleeding rates were 3.86 (95% CI 3.14–4.58), 2.93 (2.55–3.31), and 1.95 (1.65–2.25) per 100 patient‐years for warfarin, rivaroxaban, and apixaban, respectively, yielding adjusted hazard ratios (aHRs) of 0.89 (95% CI 0.71–1.12) for rivaroxaban versus warfarin, 0.55 (0.43–0.71) for apixaban versus warfarin, and 0.62 (0.50–0.76) for apixaban versus rivaroxaban. During extended treatment, major bleeding rates were 1.55 (1.19–1.91), 1.05 (0.85–1.26), and 0.96 (0.78–1.15) per 100 patient‐years for warfarin, rivaroxaban, and apixaban, respectively, with aHRs of 0.72 (0.53–0.99) for rivaroxaban versus warfarin, 0.60 (0.44–0.82) for apixaban versus warfarin, and 0.85 (0.64–1.12) for apixaban versus rivaroxaban. Previous bleeding and increasing age were risk factors for bleeding both during initial and extended treatment.ConclusionApixaban had a lower bleeding risk than warfarin or rivaroxaban during initial treatment. During extended treatment, bleeding risk was similar for apixaban and rivaroxaban, and higher with warfarin.
